Axxam supports drug discovery efforts to identify novel inhibitors for SARS-CoV-2

Apr 30, 2020

Axxam SpA (Milan/Italy), a privately-owned innovative Partner Research Organization (iPRO) announced its commitment to support the identification of antiviral therapies to treat the severe acute respiratory syndrome COVID-19, caused by the Coronavirus SARS-CoV-2.
Axxam is developing a series of in-vitro biochemical and cell-based assays using artificial pseudo-viral particles. These assays will be suitable for the identification of novel virus-specific small molecule inhibitors of SARS-CoV-2 cellular uptake and biological pathways. We will be conducting High Throughput Screening campaigns using different small molecule libraries including known/approved pharmaceutical compounds for repurposing studies.

Open PDF document